UnitedHealth Group Incorporated UNH
Healthcare · Healthcare Plans · United States · S&P 500
Based on the available data, UnitedHealth Group Incorporated gets an algorithmic score of 58/100. It trades at 374.94 $, with a bullish technical trend (RSI 40.3) and 34.3% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Sustained revenue growth (11.4% compound annual).
- Low beta (0.27): defensive profile.
Weaknesses
- —
Fundamentals
| P/E | 24.10 |
| Forward P/E | 16.58 |
| PEG | 1.01 |
| P/B | 3.45 |
| EV/EBITDA | 14.46 |
| P/S | 0.75 |
| ROE % | 14.15 |
| ROA % | 4.87 |
| Gross margin % | 19.72 |
| Operating margin % | 7.13 |
| Net margin % | 3.14 |
| Revenue growth % (y/y) | 0.40 |
| Earnings growth % (y/y) | 61.50 |
| Revenue CAGR % | 11.35 |
| Earnings CAGR % | -15.69 |
| Debt/Equity % | 69.21 |
| Current ratio | 0.78 |
| FCF yield % | 4.78 |
| Dividend yield % | 2.48 |
| Payout % | 57.52 |
Returns
| 1 month | -4.0 % |
| 3 months | -9.2 % |
| 6 months | +44.9 % |
| YTD | +13.7 % |
| 1 year | +11.9 % |
| 3 years | -21.1 % |
| 5 years | -0.5 % |
Risk
| 1-year volatility | 34.3 % |
| Beta | 0.27 |
| 5-year max drawdown | -61.4 % |
| Sharpe 1A | 0.39 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.